| Domain | Knowledge-base statement | Quantitative evidence | Suggested ontology terms/IDs | Evidence level or caveat |
|---|---|---|---|---|
| Definition / classification | Congenital primary megaureter is a pediatric imaging-defined ureteral dilatation, usually >7–8 mm, that must be etiologically classified; the key primary subtype for this entry is primary obstructive/non-refluxing megaureter (POM), i.e., distal ureterovesical junction obstruction without vesicoureteral reflux. | Diameter threshold: >7–8 mm; classified by reflux present/absent and obstruction present/absent. | Candidate terms for curator verification: MONDO primary megaureter/congenital megaureter; MeSH megaureter; UBERON ureter, ureterovesical junction; HPO Hydroureter, Hydronephrosis | Strong review-level synthesis plus primary series; nomenclature varies across sources (primary obstructive, primary non-refluxing, congenital obstructive megaureter). (pqac-00000013, pqac-00000016) |
| Data provenance | Most disease information is aggregated from disease-level reviews, retrospective pediatric cohorts, and registry studies rather than EHR-derived large population datasets. | No unified disease registry prevalence estimate identified. | Evidence model tags: human clinical; retrospective cohort; review; registry | Important for KB curation because many statements are from specialty-center series, not population-wide surveillance. (pqac-00000011, pqac-00000013, pqac-00000009) |
| Core phenotype | Typical phenotype is hydroureteronephrosis detected antenatally or in infancy/early childhood; diagnosis often follows prenatal ultrasound showing urinary tract dilatation. | CAKUT overall detectable on fetal ultrasonography; POM accessible to antenatal screening from second trimester; primary megaureter cited as 5–10% of prenatal hydronephrosis cases in one review/case-based synthesis. | HPO candidate terms: Antenatal hydronephrosis; Hydroureter; Hydronephrosis; Abnormal urinary system imaging finding | Direct disease-specific prenatal detection supported; 5–10% figure comes from later review/case literature and should be curator-verified before hard-coding. (pqac-00000009, pqac-00000004) |
| Principal clinical phenotypes | Common manifestations include urinary tract infection, progressive hydronephrosis/hydroureter, flank/loin pain, hematuria, nephrolithiasis, and loss of renal function in a subset; many infants remain asymptomatic under surveillance. | In one 79-POM surgical cohort, indications combined worsening hydroureteronephrosis with UTI, parenchymal thinning, and/or impaired differential renal function; in a small 11-case mixed megaureter series, febrile UTI occurred in 63.64% and lower back pain in 45.45%. | HPO candidate terms: Urinary tract infection; Flank pain; Hematuria; Nephrolithiasis; Decreased renal function; Renal parenchymal thinning | Symptom frequencies are highly cohort-dependent and enriched for referred/surgical patients. (pqac-00000011, pqac-00000005, pqac-00000017) |
| Anatomy affected | Primary organs: ureter and kidney collecting system; the lesion localizes to the distal/terminal ureter at the ureterovesical junction, with secondary impact on renal pelvis/calyces and renal parenchyma. | Distal obstructive/adynamic segment reported as short; one source notes 0.5–4 cm aperistaltic segment. | UBERON candidate terms: ureter; distal ureter; ureterovesical junction; renal pelvis; kidney; urinary system | Disease-specific localization is consistent across reviews and cohorts. (pqac-00000000, pqac-00000013, pqac-00000009) |
| Tissue / cell level | Pathology centers on distal ureteral smooth-muscle and extracellular-matrix abnormality, with functional aperistalsis/adynamia. | Histologic themes: focal muscle-fiber deficiency, proximal muscular hypertrophy, abnormal circular-fiber predominance, collagen infiltration/fibrosis. | CL candidate terms: smooth muscle cell; fibroblast; urothelial cell. GO candidate terms: smooth muscle contraction; extracellular matrix organization; collagen fibril organization; peristalsis | Mechanistic evidence is mainly histopathology and review synthesis, not modern single-cell data. (pqac-00000000, pqac-00000003, pqac-00000009, pqac-00000016) |
| Mechanism / causal chain | Proposed chain: congenital distal ureteral smooth-muscle differentiation defect → adynamic/aperistaltic UVJ segment → functional urinary outflow obstruction → upstream hydroureteronephrosis/tortuosity and stasis → infection, renal parenchymal thinning/scarring, and possible renal function decline. Spontaneous improvement likely reflects maturation of distal ureteral function over time. | Spontaneous resolution estimated around 72–80% in observational/review literature; maturation may continue for the first years of life. | GO candidate terms: smooth muscle cell differentiation; ureteral peristalsis; response to mechanical stress; fibrosis; kidney development | Disease-specific mechanism is plausible and repeatedly cited, but molecular drivers remain insufficiently defined. (pqac-00000013, pqac-00000016, pqac-00000000, pqac-00000009) |
| Laterality / demographics | Male predominance is typical; unilateral disease is more common, but bilateral involvement is well recognized. | Trial synopsis: affects four times more boys than girls; bilateral in 25%; contralateral renal dysplasia in 15%. Older summary: bilateral in ~25%, contralateral absence/dysplasia 10–15%. | HPO candidate terms: Bilateral hydroureter; Unilateral hydroureter; Renal dysplasia | These proportions derive from specialty literature and registry synopsis rather than population registries. (pqac-00000009, pqac-00000003) |
| Natural history | Most primary non-refluxing/obstructive megaureters improve or resolve without surgery, usually with gradual proximal-to-distal reduction in dilatation. A minority progress and require intervention. | Historic prenatal cohort: spontaneous resolution in 72% at mean >2 years; prospective data summarized in 2024 review: ureter <10 mm had 76% resolution over median 5 years vs 17% for ≥10 mm over median 9 years; 2025 conservative cohort: 57% spontaneous resolution at median 45.75 months. | HPO candidate terms: Spontaneous resolution; Persistent hydroureter; Progressive hydronephrosis | Natural-history estimates differ by inclusion criteria and era; 2025 cohort is newer but small and outside requested 2023–2024 priority window. (pqac-00000013, pqac-00000000, pqac-00000002) |
| Prognostic / resolution predictors | Worse spontaneous-resolution likelihood is associated with greater hydronephrosis severity and larger ureteral diameter. | Predictors cited: SFU grade 3–4 hydronephrosis and ureter diameter >13 mm; <10 mm vs ≥10 mm ureter threshold associated with 76% vs 17% resolution in one prospective study; 2025 cohort found hydronephrosis grade significant (p=0.046). | HPO candidate terms: Severe hydronephrosis; Enlarged ureter | Good candidate features for prognostic annotations; external validation remains limited. (pqac-00000013, pqac-00000002) |
| Diagnostics: ultrasound | Serial renal/bladder ultrasound is the backbone of diagnosis and follow-up, measuring pelvis/calyces/distal ureter diameter and renal parenchyma. | Example surveillance in one cohort: at birth, 1 month, then every 3 months during conservative follow-up; after EBD, US at 3, 6, 12, and 18 months then annually. | LOINC/RadLex candidate terms: renal/bladder ultrasound; UBERON kidney/ureter/bladder; HPO renal pelvis dilatation | Strong real-world use; exact protocols vary by center. (pqac-00000011, pqac-00000012, pqac-00000013) |
| Diagnostics: VCUG | Voiding cystourethrography is used early to exclude reflux and secondary causes; absence of reflux plus significant ureteral dilation supports POM. | Postoperative VCUG in one EBD cohort was reserved for UTI or persistent dilatation without renographic obstruction. | Candidate terms: VCUG; HPO Vesicoureteral reflux (for exclusion); UBERON bladder/urethra | Essential differential test; reflux does not absolutely exclude obstructive component in mixed/ORM cases. (pqac-00000013, pqac-00000012) |
| Diagnostics: MAG-3 renography | Diuretic renography helps assess obstruction and split renal function, but delayed washout alone should not automatically trigger surgery in an asymptomatic stable child. | Obstruction threshold in one cohort: T1/2 >20 min after furosemide; BAPU criteria summarized in 2024 review: initial DRF <40% or DRF drop ≥5% on serial scans support surgery. | Candidate terms: MAG-3 renogram; Differential renal function; Obstructive washout pattern | Important caveat: washout curves are error-prone in tortuous dilated ureters and practice varies because of radiation/cost/catheterization burden. (pqac-00000011, pqac-00000013, pqac-00000014) |
| Differential diagnosis | Secondary megaureter causes must be ruled out, including posterior urethral valves, neurogenic bladder, and other bladder outlet/voiding disorders; obstructed refluxing megaureter also exists. | No single quantitative differential metric identified. | Candidate terms: posterior urethral valves; neurogenic bladder; secondary megaureter; obstructed refluxing megaureter | Diagnosis is etiologic exclusion plus imaging pattern recognition. (pqac-00000013) |
| Conservative management | Observation is first-line for most cases; some centers use low-dose antibiotic prophylaxis during infancy/surveillance, but broader hydronephrosis literature indicates prophylaxis benefit remains controversial and should be individualized. | One POM cohort used low-dose antibiotic prophylaxis during conservative surveillance and usually stopped it by 6 months after adequate postoperative drainage; broader 2024 hydronephrosis review: CAP benefit remains controversial. | NCIT candidate interventions: Active surveillance; Antibiotic prophylaxis | Disease-specific randomized evidence for prophylaxis is lacking. (pqac-00000011, pqac-00000012, pqac-00000019) |
| Operative criteria | Intervention is generally reserved for worsening hydroureteronephrosis plus clinical or functional deterioration: febrile/recurrent UTI, pain, stones, hematuria, declining DRF, marked progressive dilation, or parenchymal thinning. | In 79 operated POMs: worsening UHN+UTI 38%; worsening UHN+parenchymal thinning 36.7%; worsening UHN+DRF impairment 17.7%; all three 7.6%. | HPO candidate terms: Progressive hydronephrosis; Recurrent urinary tract infections; Renal function decline. NCIT candidate: Surgical indication | These frequencies reflect reasons for surgery among selected operated patients, not disease prevalence. (pqac-00000011, pqac-00000016, pqac-00000017) |
| Standard surgery | Traditional gold standard is distal ureteral reimplantation/ureteroneocystostomy, with or without tapering/tailoring/remodeling. | Reported success for open reimplantation ± tapering: ~90–95% or 90–96%. | NCIT candidate interventions: Ureteral reimplantation; Ureteroneocystostomy; Ureteroplasty/tapering | High success but greater technical complexity and morbidity in infants with very dilated ureters and small bladders. (pqac-00000012, pqac-00000016, pqac-00000014) |
| Endoscopic balloon dilation (EBD/HPBD) | High-pressure balloon dilation of the UVJ has become a major minimally invasive treatment option for POM and can be definitive in many infants/children. | Systematic review: success 69–100%, may avoid surgery in up to 77%, complications 0–50% mostly infectious or stent-related; 100-case long-term series: success 87.3%, secondary VUR 21.5%, re-stenosis 12.2%, reimplantation needed in 12.7%, mean follow-up 6.4±3.8 years. | NCIT candidate interventions: Endoscopic balloon dilation; Ureteral stent placement; Endoscopic injection for VUR | Evidence is largely retrospective single-center and heterogeneous; still probably the most important recent real-world shift. (pqac-00000016, pqac-00000011, pqac-00000007, pqac-00000014) |
| Recent 2024 procedural development | Some centers now perform POM balloon dilation under cystoscopic control alone, omitting fluoroscopy to reduce ionizing radiation. | Comparative 2024 study (23 patients): hospital stay 1 vs 2 days (CS vs RX, p=0.009); OR time 30 vs 78 min (p=0.001); long-term success 100% vs 71%. | NCIT candidate interventions: Radiation-sparing endoscopic balloon dilation; Cystoscopy | Small retrospective study; promising but not definitive. (pqac-00000017) |
| Stents / temporizing drainage | Internal stents or cutaneous ureterostomy may be used as temporizing strategies, especially in infants or infection, but stents have notable complication burdens. | Review summary: older stenting literature left about half avoiding surgery after 3–6 months; more recent 35-ureter study showed only 25% avoided subsequent surgery and ~40% had stent-period issues. | NCIT candidate interventions: Ureteral stent placement; Cutaneous ureterostomy; Nephrostomy | Mostly historical/bridging role; not a definitive solution for many patients. (pqac-00000014) |
| Robotic / laparoscopic surgery | Minimally invasive reconstructive surgery is increasingly reported for selected centers and surgeons, including robotic Lich-Gregoir and other extravesical/transvesicoscopic techniques. | Robotic Lich-Gregoir series: 18 patients, 39% tapered, all improved hydronephrosis over median 2 years; multicenter comparison of 47 laparoscopic vs 48 robotic cases: 94–97% success, 2–4% high-grade complications; single-center robotic vs open: 91–92% success, 8–9% complication rates. | NCIT candidate interventions: Robotic ureteral reimplantation; Laparoscopic ureteral reimplantation | Highly center-dependent learning curve; broad uptake remains limited. (pqac-00000015) |
| Outcomes / prognosis | Renal drainage and imaging usually improve after successful intervention; long-term prognosis is generally good with preserved renal function when monitored and treated appropriately, but untreated progressive cases risk scarring/function loss. | After EBD: MAG-3 drainage improved from T1/2 >50 min baseline to 9.8±4.5 min post-op (p<0.001); mean DRF 44.4% to 46.2% (p<0.05), with no later deterioration in that series. | HPO candidate terms: Renal scarring; Chronic kidney disease; Preserved renal function | Mortality/life expectancy statistics specific to this disease were not identified. (pqac-00000012, pqac-00000009) |
| Epidemiology | Primary megaureter is an uncommon congenital urinary tract malformation within CAKUT; disease-specific population prevalence/incidence remains poorly defined. | CAKUT overall affects >1% of live births; clinical-trial synopsis calls congenital obstructive megaureter the second most common cause of hydronephrosis; one older summary cites megaureter as 23% of obstructive uropathy cases. | Candidate terms: CAKUT; congenital urinary tract obstruction | Use caution: most epidemiology is extrapolated from CAKUT/hydronephrosis or tertiary-center series, not dedicated population studies. (pqac-00000010, pqac-00000009, pqac-00000003) |
| Genetics / inheritance | No validated disease-specific monogenic cause, recurrent pathogenic variant set, inheritance pattern, penetrance estimate, or ClinGen-style gene-disease curation was identified for congenital primary megaureter itself. | None established from retrieved disease-specific evidence. | Candidate annotation: genetics unknown/heterogeneous; broader CAKUT genes for separate curation only (e.g., PAX2, TBX18, SIX2, BMP4 in CAKUT context) | Important negative finding: do not over-attribute broad CAKUT genes to primary megaureter without direct evidence. (pqac-00000010) |
| Environmental / protective factors | No disease-specific environmental risk factor, protective factor, or gene-environment interaction was identified for primary megaureter. Broader CAKUT literature implicates maternal diabetes, obesity, malnutrition, alcohol, and nephrotoxic medications in urinary tract maldevelopment generally. | None disease-specific. | Candidate annotation: environmental evidence unavailable for disease-specific entry | Keep separate from generic CAKUT etiologic risk factors. (pqac-00000010) |
| Molecular profiling / epigenetics | No validated disease-specific transcriptomic, proteomic, metabolomic, lipidomic, single-cell, spatial, or epigenetic biomarker set was identified in the retrieved evidence. | Not available. | Candidate annotation: no omics signature established | Useful KB gap statement. (pqac-00000000, pqac-00000010) |
| Other species / model organisms | No validated natural veterinary disease model or dedicated model-organism system for primary congenital megaureter was identified in retrieved evidence. | Not available. | Candidate annotation: model organism unavailable/not established | Absence of evidence from targeted search; curator may revisit specialist databases separately. (pqac-00000000) |
| Clinical trials / current research | Interventional trial activity is sparse; one relevant completed observational registry-style study is POMME. Current research focus is on optimizing selection for observation vs minimally invasive intervention and comparing endoscopic with reconstructive approaches. | POMME / NCT05639283: completed retrospective observational study, enrollment 120, University Hospital Strasbourg; no relevant gene/cell/RNA/drug trials found. | Trial IDs: NCT05639283; candidate evidence tags: observational registry, real-world study | Supports statement that management advances are procedural rather than molecular/targeted. (pqac-00000009, pqac-00000013) |


*Table: This table summarizes ontology-ready, disease-specific facts for congenital primary megaureter, emphasizing definition, pathophysiology, natural history, diagnostics, treatment, and key evidence gaps. It is designed to help curate a structured knowledge-base entry while clearly separating direct evidence from broader CAKUT context.*